TL;DR
- A new personalized mRNA vaccine shows promise in preventing melanoma recurrence.
- The vaccine reduced cancer return risk by 50% after five years.
- It trains the immune system to target lingering cancer cells.
- Results from a larger trial are awaited for confirmation.
- Low toxicity side effects similar to COVID vaccines reported.
In a groundbreaking development that could change the game for melanoma patients, a new personalized mRNA vaccine from Moderna and Merck has shown remarkable promise in keeping this deadly skin cancer from returning. According to the latest clinical trial results presented at the American Society of Clinical Oncology’s annual meeting, this innovative vaccine has halved the risk of melanoma recurrence after five years. Talk about a reason to celebrate!
Melanoma, the most lethal form of skin cancer, has a nasty habit of rearing its ugly head again—afflicting about half of patients within the first five years post-treatment. Dr. Janice Mehnert, the senior trial investigator and director of the melanoma and cutaneous medical oncology program at NYU Langone Health, emphasized, “The treatments we have are not perfect. People relapse.” But with this new vaccine, the hope is brighter than ever.
In the trial, 50 patients received the standard treatment of surgery followed by immunotherapy (hello, pembrolizumab, aka Keytruda), while another 107 patients were given the personalized vaccine tailored to their specific tumors. Fast forward five years, and nearly 70% of those who received the vaccine were cancer-free, compared to just 49% of those who stuck with the standard treatment. Now that’s what we call a major win!
The vaccine works by training the immune system to recognize and obliterate any lingering cancer cells, as well as any new ones that might pop up. Each vaccine is custom-made using genetic material from the patient’s tumor, targeting unique proteins known as neoantigens. These proteins are like a neon sign for T-cells, telling them, “Hey, here’s the bad stuff! Attack!”
https://www.youtube.com/nbcnews
Dr. Jeff Coller, a professor of RNA biology at Johns Hopkins University, praised the results, saying, “The vaccine is doing exactly what we hoped it would do.” With the mRNA technology that gained fame during the COVID pandemic, this vaccine builds on significant advances in the field. And it’s not just melanoma that’s getting this fabulous upgrade; an mRNA vaccine for pancreatic cancer is also showing potential in reducing recurrence risks.
But wait, there’s more! The trial’s results are promising, but a larger phase 3 trial involving 1,000 patients is underway to provide the real proof. Dr. Ravi Amaravadi from the University of Pennsylvania noted that most cancers tend to return within the first five years, so if patients can make it through that period without a recurrence, it’s a huge victory.
One of the standout features of this vaccine is its low toxicity. Unlike other therapies that can pack a punch with nasty side effects, this vaccine has shown side effects similar to those of mRNA COVID vaccines—think flu-like symptoms that fade within days. Dr. Shailender Bhatia from Fred Hutch Cancer Center remarked, “Generally what we have seen is that if we layer more drugs with immunotherapy, it causes more toxicity but not more benefit. So that is where the results of this trial are promising.”
As we look to the future, Mehnert and her team are eager to develop these personalized vaccines even sooner—ideally three to four weeks post-surgery. But first, they’re waiting on the results from the larger trial. If those results mirror the current findings, we could be witnessing a paradigm shift in cancer treatment, not just for melanoma, but for many other cancers as well. So, here’s to science and the hope it brings to the LGBTQ community and beyond!